The News Net


Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

news net2The Net takes a look at what’s new in Scotland and the south of France. And back in the States, the Mayo Clinic serves as a foundation for biotech hopes while an experienced bioentrepreneur is hired in Charlottesville.

  • The Scotsman profiles Glasgow University spin-out Virttu Biologics, which is seeking an £8 million infusion to further develop its virus for killing cancer cells. Says new chairman Patrick: “We’ve reached an inflection point with the company. We now need to step up a big gear and have a 24-month plan to do that.” Read it here.
  • Joe Panetta, head of San Diego’s biotech association Biocom, pens his thoughts on a business mission to the Provence-Alpes-Côte d’Azur region of France: Biotech from Nice to MarseilleRead it.
  • Could Rochester, Minnesota, be the next biotech hotspot? The backers of Destination Medical Center hope so. Mayo Clinic Ventures chairman Jim Rogers tell startup business developers that there’s governmental backing and that Rochester “is a good place to start your business, and we’re going to do what we can to make it successful.” More details in the Post-Bulletin.
  • Rochester isn’t the only place looking to build a biotech corridor off the success of Mayo Clinic. A developer plans to buy 225 acres of land near Mayo Clinic Hospital in Phoenix to develop the $1 billion Arizona Biomedical Corridor. Read by clicking.
  • Finally, the University of Virginia’s newest advocate for commercializing its research discoveries brings nearly 30 years of experience in the biotech and pharma industries. UVa alumni Brian Pollok has been named the university’s first entrepreneur-in-residence. He will offer guidance, perspective and a voice on how researchers can amplify their discoveries, working with UVa Innovation and the university’s licensing and ventures group. Find out more.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Life Sciences > Biological Sciences > Biotechnology